ストックスクリーナーアプリを入手
17.97
0.06%
-0.04
前日終値:
$17.93
開ける：
$17.85
24時間の取引高:
17,539
Relative Volume:
0.13
時価総額：
$670.94M
収益：
$239.40M
当期純損益:
$104.44M
株価収益率:
-6.9651
EPS:
-2.58
ネットキャッシュフロー:
$-18.50M
1週間 パフォーマンス:
-5.88%
1か月 パフォーマンス:
+3.46%
6か月 パフォーマンス:
+14.14%
1年 パフォーマンス:
+7.50%
1日の値動き範囲:
$17.60
$17.98
1週間の範囲:
$17.09
$19.23
52週間の値動き範囲:
$10.75
$20.49
Entrada Therapeutics Inc Stock (TRDA) Company Profile
名前
Entrada Therapeutics Inc
セクター
電話
857-305-1825
住所
ONE DESIGN CENTER PLACE, BOSTON
TRDA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| TRDA | 17.97 | 670.94M | 239.40M | 104.44M | -18.50M | -2.58 |
| VRTX | 446.50 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 739.88 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.80 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.97 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.80 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-05 | 開始されました | Oppenheimer | Outperform |
| 2023-04-03 | 開始されました | H.C. Wainwright | Buy |
Entrada Therapeutics Inc (TRDA) 最新ニュース
Los Angeles Capital Management LLC Makes New $542,000 Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Insider Sale at Entrada Therapeutics Inc (TRDA) by President of Research & Development - GuruFocus.com
500: Something went wrong - Investing.com UK
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates - MSN
HC Wainwright Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - Defense World
HC Wainwright Analysts Boost Earnings Estimates for TRDA - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Entrada Therapeutics president sells shares worth $339,280 By Investing.com - Investing.com Australia
Equities Analysts Issue Forecasts for TRDA FY2024 Earnings - MarketBeat
HC Wainwright Has Positive Outlook of TRDA FY2024 Earnings - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock - Benzinga
Oppenheimer Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - MarketBeat
Entrada Therapeutics stock target increased on positive trial data By Investing.com - Investing.com UK
Entrada Therapeutics (NASDAQ:TRDA) Price Target Raised to $20.00 - MarketBeat
Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Entrada Therapeutics’ Q3 2024 Financial Highlights - TipRanks
Entrada Therapeutics (NASDAQ:TRDA) Hits New 12-Month HighHere's What Happened - MarketBeat
Entrada Therapeutics stock hits 52-week high at $18.22 By Investing.com - Investing.com UK
Entrada Therapeutics : Corporate Presentation - Marketscreener.com
Entrada Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going - MSN
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Short Interest Down 19.1% in October - MarketBeat
Short Interest in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Declines By 19.1% - Defense World
Here's What Could Help Entrada Therapeutics (TRDA) Maintain Its Recent Price Strength - MSN
Entrada Therapeutics president sells $10,800 in stock By Investing.com - Investing.com Australia
Natarajan Sethuraman Sells 600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock - MarketBeat
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding - Simply Wall St
Oppenheimer Initiates Coverage of Entrada Therapeutics (TRDA) with Outperform Recommendation - MSN
(TRDA) Trading Report - Stock Traders Daily
The Manufacturers Life Insurance Company Purchases 2,146 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Renaissance Technologies LLC Invests $636,000 in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics advances Duchenne treatment trials - Investing.com
Entrada Therapeutics advances Duchenne treatment trials By Investing.com - Investing.com UK
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society - The Manila Times
HRMY: 3 Small-Cap Biotech Stocks to Buy for Major Upside - StockNews.com
(TRDA) Trading Advice - Stock Traders Daily
Morguard Un (MRT-UN-T) QuotePress Release - The Globe and Mail
Pompe Disease Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Market Dynamics, MOA, ROA by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas - The Globe and Mail
Entrada Therapeutics COO sells shares worth over $13,000 - Investing.com India
Entrada Therapeutics COO sells shares worth over $13,000 By Investing.com - Investing.com Australia
Insider Sale: President & COO Nathan Dowden Sells Shares of Entr - GuruFocus.com
Entrada Therapeutics (NASDAQ:TRDA) Trading 4.8% Higher - MarketBeat
U.S. Gold Corp (USAU-Q) QuotePress Release - The Globe and Mail
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development - Markets Insider
Entrada Therapeutics appoints new President of R&D - Investing.com
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
Entrada Therapeutics Inc (TRDA) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):